What does Equillium, Inc. do?
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung…
What is Equillium, Inc.'s P/E and P/B ratio?
Equillium, Inc. has a P/E ratio of -8.8 and a P/B ratio of 1.39.
What is Equillium, Inc.'s debt-to-equity ratio?
Equillium, Inc. has a debt-to-equity ratio of 0.01.
How much does Equillium, Inc. owe compared with what it owns?
Equillium, Inc. owes $0.05 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Equillium, Inc.'s Positivity rank?
Equillium, Inc. is ranked #1,934 of 6,775 companies globally and #491 of 3,999 in United States on PositoAI, with a Positivity Score of 22,187.
Does Equillium, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Equillium, Inc..
Where can I read the latest news about Equillium, Inc.?
Recent headlines about Equillium, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Equillium, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Equillium, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.